GE HEALTHCARE TECHNOLOGIES INC.
GE HealthCare Technologies Inc. (GEHC) is a global medical technology and services company focused on diagnostic imaging, ultrasound, patient monitoring, life‑sciences tools and bioprocessing, and healthcare IT. With a market capitalisation around $34.7 billion, the business combines capital equipment sales with recurring revenue from service contracts, consumables and software – a mix that can smooth cyclicality in equipment purchases. Key growth drivers include demand for imaging and diagnostics, expansion of bioprocessing for biologics, and adoption of digital and AI tools to improve workflows. Investors should be aware of sensitivity to hospital and clinic capital spending cycles, competitive pressures, reimbursement and regulatory risk, and supply‑chain dynamics. Management execution and capital allocation also matter for returns. This summary is educational only, not personalised advice: values can rise and fall and past performance is not a guide to the future. Check up‑to‑date filings and consult a financial adviser when assessing suitability for your portfolio.
Why It's Moving
GE HealthCare prices $1.25B notes offering, fueling investor bets on expansion amid recent gains.
GE HealthCare Technologies announced a $1.25 billion senior notes offering this week, split between notes due 2028 and 2035, set to close around December 15. The move signals confidence in growth prospects for its medical tech portfolio, coinciding with shares climbing over 1.9% on Thursday to $86.09.[2][3]
- Priced $600M in 4.15% notes due 2028 and $650M in 4.95% notes due 2035, bolstering liquidity without straining its moderate debt-to-equity ratio of 1.08.[3]
- Stock surged 1.91% on December 11 to $86.09, with opening at $85.72 on December 12, reflecting positive market reception to the debt raise.[2][7]
- Underwritten by Goldman Sachs and BNP Paribas, the offering underscores strategic capital access amid healthcare sector demand for advanced imaging tech.[3]
GE HealthCare prices $1.25B notes offering, fueling investor bets on expansion amid recent gains.
GE HealthCare Technologies announced a $1.25 billion senior notes offering this week, split between notes due 2028 and 2035, set to close around December 15. The move signals confidence in growth prospects for its medical tech portfolio, coinciding with shares climbing over 1.9% on Thursday to $86.09.[2][3]
- Priced $600M in 4.15% notes due 2028 and $650M in 4.95% notes due 2035, bolstering liquidity without straining its moderate debt-to-equity ratio of 1.08.[3]
- Stock surged 1.91% on December 11 to $86.09, with opening at $85.72 on December 12, reflecting positive market reception to the debt raise.[2][7]
- Underwritten by Goldman Sachs and BNP Paribas, the offering underscores strategic capital access amid healthcare sector demand for advanced imaging tech.[3]
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying GE Healthcare Technologies' stock, anticipating it could rise significantly in value.
Financial Health
GE Healthcare is performing well, showing solid profits and cash flow, with strong revenue growth.
Dividend
GE Healthcare's low dividend yield of 0.2% indicates limited returns for dividend-seeking investors. If you invested $1000 you would be paid $2 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GEHC
Healthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: September 22, 2025
Explore BasketARK Innovation ETF: What's Next for Africa's Growth?
Africa's digital economy is rapidly expanding, creating demand for cutting-edge technologies in finance, healthcare, and energy. This basket offers potential exposure to US-listed companies leading the disruptive innovation trends that are shaping the continent's future.
Published: September 15, 2025
Explore BasketHealthcare's Efficiency Imperative
UnitedHealth Group's recent profit miss, driven by high medical costs, has triggered a major cost-cutting initiative across the company. This move signals a broader industry trend, creating an investment opportunity in companies that provide AI and technology solutions to help healthcare organizations improve efficiency and reduce operational expenses.
Published: July 30, 2025
Explore BasketHealthcare's Compliance Catalyst
The Department of Justice's investigation into UnitedHealth's billing practices is increasing pressure on the entire healthcare industry to ensure compliance. This regulatory focus creates an investment opportunity in companies that provide specialized technology for transparent and accurate medical billing.
Published: July 26, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Diagnostics and Imaging
Imaging equipment drives sales and higher‑margin service revenue; technological upgrades and AI could support demand, though hospital budgets and reimbursement affect timing.
Life Sciences Growth
Bioprocessing and tools for biologics offer expansion opportunities as biologics production rises, but competition and capital intensity can affect margins.
Global Service Network
Recurring revenue from service contracts and consumables provides stability and customer ties, yet geographic exposure and supply chains can influence performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
